PIK3CD and neoplasm: Venkatesan et al [48] reported a series of novel 2-aryl or heteroaryl substituted-4-morpholino imidazolopyrimidine derivatives (81-82) as moderate to potent dual PI3K/mTOR inhibitors (PI3Kα IC50 ~11-189 nM, PI3Kγ IC50 ~ 47-10000nM, mTOR IC50 ~ 51-7200 nM), which had good tumor cell growth inhibition and suppression of pathway specific biomarkers such as phosphorylation of Akt.